

For further Information contact:
Richard J. Freer, PhD.
Chairman & COO
Commonwealth Biotechnologies, Inc.
804-648-3820

FOR IMMEDIATE RELEASE

**Commonwealth Biotechnologies, Inc. Acknowledged by the Department of
Defense for Support of the Guard and Reserves**

*Special briefing held at the Pentagon at the invitation of Donald H. Rumsfeld, Secretary
of Defense.*

RICHMOND, VA (July 22, 2003) - Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ SmallCap Market: CBTE), a life sciences contract research organization and biotechnology company, attended a special briefing at the Pentagon on July 18 at the invitation of Secretary of Defense, Donald H. Rumsfeld. The briefing was hosted by Assistant Secretary of Defense (Reserve Affairs) Thomas F. Hall and acknowledged CBI along with 20 other companies as having provided extraordinary support of the Guard and Reserves during times of national need. The briefing was presented by General Richard B. Myers, Chairman, Joint Chiefs of Staff and Secretary Rumsfeld

"CBI was honored to receive this recognition by the Department of Defense. We are especially pleased that the efforts of small businesses like ours are recognized and appreciated and that our input is valued", said Dr. Richard J. Freer, Chairman and COO.

Secretary Tom Hall, the Assistant Secretary of Defense indicated that, " It is Important for the Department of Defense to meet with and receive input from the employers of America with respect to their experience with the Guard and Reserve. The Department of Defense intends to continue these vital meetings in the future."

About CBI:

Founded in 1992, CBI is located at 601 Biotech Drive, Richmond, VA 23235 (1-800-735-9224). CBI has provided comprehensive research and development services to more than 2,700 private, government, and academic customers in the global biotechnology industry. For more information, visit CBI on the web at www.cbi-biotech.com.

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Actual results, events, or performance may differ materially. No statement herein should be considered an offer of any securities. Such an offer can only be made in accordance with federal and applicable state securities laws. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof.